Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 381.40
-5.15 (-1.33%)
At close: Jan 23, 2026
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 148 billion as of January 23, 2026. Its market cap has decreased by -47.23% in one year.
Market Cap
148.00B
Enterprise Value
149.87B
Revenue
12.11B
Ranking
n/a
PE Ratio
83.62
Stock Price
381.40
Market Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 148.00B, an increase of 438,992.41%. That is a compound annual growth rate of 316.71%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 22, 2026 | 148.00B | -26.82% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| J. B. Chemicals & Pharmaceuticals | 288.39B |
| AstraZeneca Pharma India | 208.68B |
| Jubilant Pharmova | 153.37B |
| Granules India | 138.61B |
| Caplin Point Laboratories | 130.85B |
| Rubicon Research | 109.49B |
| Sanofi India | 93.40B |
| Procter & Gamble Health | 89.85B |